• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

PDT offers good response, recurrence rates for multiple BCCs

Article

Vancouver, Canada - ALA-PDT is the treatment of choice for patients with multiple superficial basal cell carcinomas on the face, trunk, or scalp, particularly because of its excellent cosmetic results, Willem Star, Ph.D., said at the World Congress of Photodynamic Therapy.

Recent Videos
Andrew Alexis, MD, MPH, an expert on vitiligo
Andrew Alexis, MD, MPH, an expert on vitiligo
Andrew Alexis, MD, MPH, an expert on vitiligo
Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis
Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis
This series features 1 KOL.
This series features 1 KOL.
Related Content
The Weekly Roundup: July 22-26

The Weekly Roundup: July 22-26

Article
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis

The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis

Podcast
Emerging Therapeutic for Non-Segmental Vitiligo: Merck’s MK-6194

Emerging Therapeutic for Non-Segmental Vitiligo: Merck’s MK-6194

Article
The Cutaneous Connection: Enhancing Vitiligo Care With Nanette Silverberg, MD

The Cutaneous Connection: Enhancing Vitiligo Care With Nanette Silverberg, MD

Podcast
Study Highlights Efficacy of Lotion with Biotechnological Phytocomplex, Niacinamide, and Succinic Acid in Enhancing Microbiota Diversity and Reducing Acne Severity

Study Highlights Efficacy of Lotion with Biotechnological Phytocomplex, Niacinamide, and Succinic Acid in Enhancing Microbiota Diversity and Reducing Acne Severity

Article
The FDA Approves Deuruxolitinib for Severe Alopecia in Adults

The FDA Approves Deuruxolitinib for Severe Alopecia in Adults

Article
© 2024 MJH Life Sciences

All rights reserved.